Cancer
Our cancer research examines many of the most prevalent cancers today with the goal of finding new and innovative therapies, treatments and ultimately prevention and cures.
Our researchers discovered a link between finasteride, a medication used to relieve urinary problems, and prevention of prostate cancer.
The Mays Cancer Center is a member of The Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC).
Clinical trial participation is an invaluable way to contribute to the pursuit of new treatments for cancer. Take action today...volunteer and play a role in finding a cure.
Find
Congratulations to our 2017-2018 CPRIT grants recipients! As a community of scientists, every dollar invested in research and core facilities by CPRIT is a win-win. Collectively, the awardees received $10,079,084 in 2017-2018!
Additional Highlights
-
Cancer center partnership advantageous
There is much to gain by having The University of Texas Health Science Center and MD Anderson, the top-ranked cancer-treatment hospital in the country, collaborate on expanding the services available in San Antonio.
Read more at the San Antonio Express-News -
Voelcker Fund award $2.3 million for young faculty research, pipeline education
William L. Henrich, M.D., MACP, president of UT Health San Antonio, on June 26 announced that the Max and Minnie Tomerlin Voelcker Fund is giving $1.45 million to the university to support three innovative research projects and one pilot research project, all conducted by rising young faculty studying cancer and cardiovascular disease.
Read the article at UT Health San Antonio's Newsroom -
Tiny molecule has big effect in childhood brain tumor studies
A new study by UT Health San Antonio researchers found that a molecule thousands of times smaller than a gene is able to kill medulloblastoma, the most common childhood brain cancer.
Read the article at UT Health San Antonio's Newsroom -
Study: Gemcitabine helps prevent recurrence of low-grade bladder cancer
A multi-institution clinical trial involving researchers from UT Health San Antonio shows significantly lower recurrence of bladder cancer in patients who received the chemotherapy drug gemcitabine.
Read the article at UT Health San Antonio's Newsroom